ClinicalTrials.gg
CompletedNCT01392469Updated Jun 21, 2021Results posted

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

A Phase 3 interventional study of Imatinib and Sildenafil in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.

Enrollment
11th of 18
21 · median 23
Started
2011
the only one that year
Phase 3
7 of 18
none open now
Registered
13th of 18
by date
Lead sponsor
1 of 18
Novartis Pharmaceuticals

Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 13th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sildenafil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Arterial Hypertension
  • Pulmonary Vascular Resistance
  • Imatinib
  • Bosentan
  • Sildenafil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Pulmonary arterial hypertension (PAH) in World Health Organization (WHO) Diagnostic Group 1, with pulmonary vascular resistance > 800 dyne*sec*cm\^-5,
  • On stable doses of bosentan and sildenafil

Exclusion criteria

Exclusion Criteria:

  • Other diagnosis of PAH in World Health Organization (WHO) Diagnostic Group 1 such as congenital large or small unrepaired systemic to pulmonary shunts, portal hypertension, (HIV) infection, glycogen storage disease, Gaucher's disease, hereditary hemorrhagic teleangiectasia, hemoglobinopathies, myeloproliferative disorders, veno-occlusive pulmonary disease
  • Significant lung diseases not related to PAH
  • Significant cardiovascular system disorders, hematological system disorders, liver insufficiency
  • Significant diseases in other organ system.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Imatinib + Bosentan + Sildenafil

    Participants received treatment with bosentan 125 milligrams (mg) twice daily and sildenafil thrice daily for 8 days in treatment period 1. Participants were on the same sildenafil dose level (20, 40, 50 or 60 mg) they had been at study entry which was well tolerated in conjunction with bosentan. Following treatment period 1, the participants received concomitant treatment of oral imatinib 200 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 2. Following treatment period 2, the participants received concomitant treatment of oral imatinib 400 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 3.

    Drug: Imatinib · Drug: Sildenafil · Drug: Bosentan

Interventions

  • Film coated tablets, oral administration

    Also known as: QTI571

  • Oral Administration

  • Oral Administration

06

What researchers measure

Primary outcomes

  1. Geometric Mean Ratio of Dose Normalized Area Under the Curve From Time Zero to Tau (AUCtau) for Bosentan Before and After Imatinib Administrations

    AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized AUCtau of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).

    Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

  2. Geometric Mean Ratio of Dose Normalized AUCtau for Sildenafil Before and After Imatinib Administrations

    AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized AUCtau of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).

    Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

  3. Geometric Mean Ratio of Dose Normalized Maximum Plasma Concentration (Cmax) for Bosentan Before and After Imatinib Administrations

    Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized Cmax of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).

    Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

  4. Geometric Mean Ratio of Dose Normalized Cmax for Sildenafil Before and After Imatinib Administrations

    Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized Cmax of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals was then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).

    Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

Secondary outcomes

  1. Number of Participants With At Least One or More Adverse Events (AEs)

    An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition that occurred after starting the study drug even if the event was not considered to be related to study drug. Number of participants with AEs were reported by treatment period.

    Time frame: From time of first administration of study drug until end of study (up to approximately 18 months)

  2. Dose Normalized Cmax of Imatinib and CGP74588 (Active Metabolite of Imatinib)

    Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

  3. Dose Normalized AUCtau of Imatinib and CGP74588 (Active Metabolite of Imatinib)

    Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

07

Results

Posted Jun 21, 2021

Participant flow

Participants with pulmonary arterial hypertension (PAH) were enrolled in the study at 8 investigation sites worldwide from 20 April 2011 to 25 October 2012.

Participant flow — Overall Study
MilestoneImatinib+ Bosentan+ Sildenafil
Started21
Completed17
Not completed4
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1
Withdrew: Protocol violation1

Outcome measures

PrimaryGeometric Mean Ratio of Dose Normalized Area Under the Curve From Time Zero to Tau (AUCtau) for Bosentan Before and After Imatinib Administrations

AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized AUCtau of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).

Time frame:
Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · hr*ng/mL/mg
Geometric Mean Ratio of Dose Normalized Area Under the Curve From Time Zero to Tau (AUCtau) for Bosentan Before and After Imatinib Administrations
hr*ng/mL/mgBosentan + Sildenafil (Reference)Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1)Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2)
Geometric Mean Ratio of Dose Normalized Area Under the Curve From Time Zero to Tau (AUCtau) for Bosentan Before and After Imatinib Administrations93.3 ± 49.9109 ± 52.0131 ± 38.0
Statistical analysis
  • Bosentan + Sildenafil (Reference) vs Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1) · Ratio (test/reference): 1.17 · 90% CI 1.03 to 1.33
  • Bosentan + Sildenafil (Reference) vs Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2) · Ratio (test/reference): 1.40 · 90% CI 1.23 to 1.59
PrimaryGeometric Mean Ratio of Dose Normalized AUCtau for Sildenafil Before and After Imatinib Administrations

AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized AUCtau of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).

Time frame:
Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · hr*ng/mL/mg
Geometric Mean Ratio of Dose Normalized AUCtau for Sildenafil Before and After Imatinib Administrations
hr*ng/mL/mgBosentan + Sildenafil (Reference)Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1)Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2)
Geometric Mean Ratio of Dose Normalized AUCtau for Sildenafil Before and After Imatinib Administrations7.22 ± 60.69.82 ± 42.512.3 ± 40.9
Statistical analysis
  • Bosentan + Sildenafil (Reference) vs Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1) · Ratio (test/reference): 1.36 · 90% CI 1.14 to 1.62
  • Bosentan + Sildenafil (Reference) vs Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2) · Ratio (test/reference): 1.70 · 90% CI 1.43 to 2.03
PrimaryGeometric Mean Ratio of Dose Normalized Maximum Plasma Concentration (Cmax) for Bosentan Before and After Imatinib Administrations

Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized Cmax of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).

Time frame:
Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · ng/mL/mg
Geometric Mean Ratio of Dose Normalized Maximum Plasma Concentration (Cmax) for Bosentan Before and After Imatinib Administrations
ng/mL/mgBosentan + Sildenafil (Reference)Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1)Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2)
Geometric Mean Ratio of Dose Normalized Maximum Plasma Concentration (Cmax) for Bosentan Before and After Imatinib Administrations21.9 ± 48.821.8 ± 60.323.4 ± 44.7
Statistical analysis
  • Bosentan + Sildenafil (Reference) vs Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1) · Ratio (test/reference): 1.00 · 90% CI 0.82 to 1.21
  • Bosentan + Sildenafil (Reference) vs Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2) · Ratio (test/reference): 1.07 · 90% CI 0.88 to 1.31
PrimaryGeometric Mean Ratio of Dose Normalized Cmax for Sildenafil Before and After Imatinib Administrations

Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized Cmax of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals was then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).

Time frame:
Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Geometric mean · ng/mL/mg
Geometric Mean Ratio of Dose Normalized Cmax for Sildenafil Before and After Imatinib Administrations
ng/mL/mgBosentan + Sildenafil (Reference)Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1)Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2)
Geometric Mean Ratio of Dose Normalized Cmax for Sildenafil Before and After Imatinib Administrations2.44 ± 68.63.14 ± 52.43.81 ± 52.9
Statistical analysis
  • Bosentan + Sildenafil (Reference) vs Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1) · Ratio (test/reference): 1.28 · 90% CI 1.03 to 1.61
  • Bosentan + Sildenafil (Reference) vs Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2) · Ratio (test/reference): 1.56 · 90% CI 1.24 to 1.95
SecondaryNumber of Participants With At Least One or More Adverse Events (AEs)

An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition that occurred after starting the study drug even if the event was not considered to be related to study drug. Number of participants with AEs were reported by treatment period.

Time frame:
From time of first administration of study drug until end of study (up to approximately 18 months)
Reported as:
Count of participants · Participants
Number of Participants With At Least One or More Adverse Events (AEs)
ParticipantsBosentan + SildenafilImatinib (200 mg/Day) + Bosentan + SildenafilImatinib (400 mg/Day) + Bosentan+ Sildenafil
Number of Participants With At Least One or More Adverse Events (AEs)10916
SecondaryDose Normalized Cmax of Imatinib and CGP74588 (Active Metabolite of Imatinib)
Time frame:
Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Mean · ng/ml/mg
Dose Normalized Cmax of Imatinib and CGP74588 (Active Metabolite of Imatinib)
ng/ml/mgImatinib (200 mg/Day) + Bosentan + SildenafilImatinib (400 mg/Day) + Bosentan + Sildenafil
Imatinib Cmax/Dose7.55 ± 4.186.71 ± 3.39
CGP74588 Cmax/Dose1.37 ± 0.5381.39 ± 0.575
SecondaryDose Normalized AUCtau of Imatinib and CGP74588 (Active Metabolite of Imatinib)
Time frame:
Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Reported as:
Mean · hr*ng/mL/mg
Dose Normalized AUCtau of Imatinib and CGP74588 (Active Metabolite of Imatinib)
hr*ng/mL/mgImatinib (200 mg/Day) + Bosentan + SildenafilImatinib (400 mg/Day) + Bosentan + Sildenafil
Imatinib AUCtau/Dose90.9 ± 49.388.4 ± 36.0
CGP74588 AUCtau/Dose19.3 ± 9.6920.6 ± 9.07

Adverse events

Collected over From time of first administration of study drug until end of study (up to approximately 18 months). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bosentan + Sildenafil0/21 (0%)0/21 (0%)10/21 (47.6%)
Imatinib (200 mg/Day) + Bosentan + Sildenafil0/19 (0%)2/19 (10.5%)9/19 (47.4%)
Imatinib (400 mg/Day) + Bosentan+ Sildenafil0/18 (0%)1/18 (5.6%)16/18 (88.9%)
Total Participants0/21 (0%)2/21 (9.5%)19/21 (90.5%)
Most frequent serious events
Most frequent serious events
EventBosentan + SildenafilImatinib (200 mg/Day) + Bosentan + SildenafilImatinib (400 mg/Day) + Bosentan+ SildenafilTotal Participants
Atrial flutterCardiac disorders0/210/191/181/21
RashSkin and subcutaneous tissue disorders0/210/191/181/21
Cardiac failure congestiveCardiac disorders0/211/190/181/21
Viral infectionInfections and infestations0/211/190/181/21
Most frequent other events
Showing 10 of 59
Most frequent other events
EventBosentan + SildenafilImatinib (200 mg/Day) + Bosentan + SildenafilImatinib (400 mg/Day) + Bosentan+ SildenafilTotal Participants
DiarrhoeaGastrointestinal disorders1/215/192/187/21
NauseaGastrointestinal disorders1/214/192/187/21
VomitingGastrointestinal disorders0/211/194/185/21
Oedema peripheralGeneral disorders2/211/193/185/21
AnaemiaBlood and lymphatic system disorders1/211/193/184/21
Blood potassium decreasedInvestigations0/211/193/184/21
HeadacheNervous system disorders1/212/191/184/21
DizzinessNervous system disorders3/210/190/183/21
Urinary tract infectionInfections and infestations0/210/192/182/21
Muscle spasmsMusculoskeletal and connective tissue disorders0/210/192/182/21

Baseline characteristics

Safety analysis set included all participants enrolled and who received at least one dose of study drug (bosentan, sildenafil, or imatinib).

Age, Continuous
Age, Continuous(years)Imatinib+ Bosentan+ Sildenafil
Mean54.4 ± 13.44
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib+ Bosentan+ Sildenafil
Female15
Male6
08

Study locations

11 sites
  • Novartis Investigative Site
    Tampa, Florida 33606, United States
  • Novartis Investigative Site
    Weston, Florida 33331, United States
  • Novartis Investigative Site
    Mineola, New York 11501, United States
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Berlin, 12683, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Vilnius, LT-08661, Lithuania
  • Novartis Investigative Site
    London, NW3 2PR, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2011 to primary completion in Oct 2012, 18 months.

Results were first posted in Jun 2021, 8 years 7 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 18 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2011
First posted
Jul 12, 2011
StartActual
Apr 20, 2011
Primary completionActual
Oct 25, 2012
CompletionActual
Oct 25, 2012
Results first posted
Jun 21, 2021
Last update
Jun 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01392469
Responsible party
Sponsor
First posted
Jul 12, 2011
Start date
Apr 20, 2011
Primary completion
Oct 25, 2012
Completion
Oct 25, 2012
Results posted
Jun 21, 2021
Last update
Jun 21, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Imatinib · Sildenafil · Bosentan

Start the discussion